logo
Plus   Neg
Share
Email

BioNTech: COVID-19 Vaccines Manufactured At Marburg Site Scheduled For Distribution In April

BioNTech SE (BNTX) said the company's new BioNTech site will become one of the largest mRNA manufacturing sites in Europe with an annual production capacity of up to 750 million doses of COVID-19 vaccine, once fully operational. The company said the first vaccines manufactured at the Marburg site are scheduled for distribution in early April.

BioNTech SE started the manufacturing process at the Marburg facility with the execution of the first step: the production of mRNA. The company noted that, to allow for supply of drug product from the site in Marburg, the production processes of the new facility need to be approved based on reviewing a range of quality and validation data by the European Medicines Agency. The validation, as well as the submission of data and other required information, will take place in February and March.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
Follow RTT